• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Study Purpose

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • - Life expectancy of at least 6 months, as determined by the investigator.
  • - Histologically or cytologically confirmed with unresectable or metastatic HER2-positive advanced solid tumors.
  • - Must be relapsed or refractory after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received first-line induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen.
  • - Participants with new, untreated, progressive, or stable brain metastases are eligible.

Exclusion Criteria:

  • - Participation in any other clinical study involving an investigational drug or device within 4 weeks prior to the first dose of study treatment.
- Any intracranial lesion (brain metastasis) that requires immediate local therapy, such as surgery or radiation, or systemic corticosteroids at the time of enrollment

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05593094
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Hoffmann-La Roche
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Clinical Trials
Principal Investigator Affiliation Hoffmann-La Roche
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Australia, France, Italy, New Zealand, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Advanced Solid Tumors, HER2-positive Breast Cancer
Additional Details

This study is composed of three parts designed to evaluate the safety and efficacy of ZN-A-1041 in participants with HER2-positive advanced solid tumors. Phase 1a (Monotherapy Dose Escalation): In this first phase, participants will receive ZN-A-1041 alone. The study will begin with a low dose of ZN-A-1041, which will be gradually increased in new groups of participants to find the highest dose that can be given safely. This will establish the recommended dose for further study. Phase 1b (Combination Dose Escalation): In the second phase, the study will evaluate the safety of giving ZN-A-1041 together with established standard-of-care therapies for HER2-positive breast cancer. Participants will be enrolled into one of three combination arms to receive ZN-A-1041 with either T-DM1, T-DXd, or a pertuzumab/trastuzumab-based regimen. This phase will identify the recommended dose for these combination therapies. Phase 1c (Combination Dose Expansion): In the final phase, additional participants will be enrolled to receive ZN-A-1041 at the recommended combination doses identified in Phase 1b. This will allow for a more thorough evaluation of the safety and preliminary efficacy of these treatment regimens. Throughout the study, participants will undergo screening, treatment, and follow-up periods to collect comprehensive data on the safety, tolerability, pharmacokinetics, and anti-tumor activity of ZN-A-1041, both as a single agent and in combination.

Arms & Interventions

Arms

Experimental: 1a: ZN-A-1041

Phase 1a: Participants will receive escalating doses of ZN-A-1041 orally twice a day (BID) at pre-defined dosing regimens to determine the maximum tolerated dose (MTD).

Experimental: 1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.

Phase 1b Arm1: 1. If the maximum tolerated dose (MTD) of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

Experimental: 1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.

Phase 1b Arm2: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

Experimental: 1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta

Phase 1b Arm3: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

Experimental: 1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.

Phase 1c Arm1: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

Experimental: 1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.

Phase 1c Arm2: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

Experimental: 1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO

Phase 1c Arm3: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

Interventions

Drug: - ZN-A-1041

ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD

Drug: - ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b

ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Drug: - ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b

ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Drug: - ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b

ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion

Drug: - ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c

ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Drug: - ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c

ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Drug: - ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c

ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Tucson 5318313, Arizona 5551752

Status

Address

Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa

Tucson 5318313, Arizona 5551752, 85712

TOI Clinical Research, Cerritos 5335663, California 5332921

Status

Address

TOI Clinical Research

Cerritos 5335663, California 5332921, 90703-2684

UCSF Helen Diller Family CCC, San Francisco 5391959, California 5332921

Status

Address

UCSF Helen Diller Family CCC

San Francisco 5391959, California 5332921, 94158

Dana Farber Cancer Institute, Boston 4930956, Massachusetts 6254926

Status

Address

Dana Farber Cancer Institute

Boston 4930956, Massachusetts 6254926, 02215

University of Michigan Hospital, Ann Arbor 4984247, Michigan 5001836

Status

Address

University of Michigan Hospital

Ann Arbor 4984247, Michigan 5001836, 48109

Barbara Ann Karmanos Cancer Institute, Detroit 4990729, Michigan 5001836

Status

Address

Barbara Ann Karmanos Cancer Institute

Detroit 4990729, Michigan 5001836, 48201

Duke University School of Medicine, Durham 4464368, North Carolina 4482348

Status

Address

Duke University School of Medicine

Durham 4464368, North Carolina 4482348, 27710

MD Anderson Cancer Center, Houston 4699066, Texas 4736286

Status

Address

MD Anderson Cancer Center

Houston 4699066, Texas 4736286, 77030-4000

International Sites

Geelong Hospital, Geelong 2165798, Victoria 2145234, Australia

Status

Address

Geelong Hospital

Geelong 2165798, Victoria 2145234, 3220

Sunshine Hospital, St Albans 8015209, Victoria 2145234, Australia

Status

Address

Sunshine Hospital

St Albans 8015209, Victoria 2145234, 3021

EDOG - Institut Claudius Regaud - PPDS, Toulouse 2972315, Haute-Garonne, France

Status

Address

EDOG - Institut Claudius Regaud - PPDS

Toulouse 2972315, Haute-Garonne, 31059

Centre Georges Francois Leclerc, Dijon 3021372, France

Status

Address

Centre Georges Francois Leclerc

Dijon 3021372, , 21000

Centre Oscar Lambret, Lille 2998324, France

Status

Address

Centre Oscar Lambret

Lille 2998324, , 59020

Lyon 2996944, France

Status

Address

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

Lyon 2996944, , 69373

Institut Paoli-Calmettes, Marseille 2995469, France

Status

Address

Institut Paoli-Calmettes

Marseille 2995469, , 13009

Institut de Cancerologie de l Ouest, Saint-Herblain 2979590, France

Status

Address

Institut de Cancerologie de l Ouest

Saint-Herblain 2979590, , 44805

Gustave Roussy, Villejuif 2968705, France

Status

Address

Gustave Roussy

Villejuif 2968705, , 94800

Parma 3171457, Emilia-Romagna 3177401, Italy

Status

Address

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS

Parma 3171457, Emilia-Romagna 3177401, 43126

Asst Papa Giovanni XXIII, Bergamo 3182164, Lombardy 3174618, Italy

Status

Address

Asst Papa Giovanni XXIII

Bergamo 3182164, Lombardy 3174618, 24127

Magnago 3174250, Lombardy 3174618, Italy

Status

Address

Fondazione Policlinico Universitario A Gemelli-Rome

Magnago 3174250, Lombardy 3174618, 20020

Auckland City Hospital, Auckland 2193733, New Zealand

Status

Address

Auckland City Hospital

Auckland 2193733, , 1023

Argentona 3129607, Barcelona, Spain

Status

Address

Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

Argentona 3129607, Barcelona, 08310

Santiago de Compostela 3109642, LA Coruna, Spain

Status

Address

Hospital Clinico Universitario de Santiago

Santiago de Compostela 3109642, LA Coruna, 15706

Hospital Universitario Ramon y Cajal, A Gudiña 3119641, Orense, Spain

Status

Address

Hospital Universitario Ramon y Cajal

A Gudiña 3119641, Orense, 32540

Hospital Universitario Virgen del Rocio, Las Cabezas de San Juan 2515493, Sevilla, Spain

Status

Address

Hospital Universitario Virgen del Rocio

Las Cabezas de San Juan 2515493, Sevilla, 41730

Barcelona 3128760, Spain

Status

Address

Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud

Barcelona 3128760, , 08028

Hospital Clinic de Barcelona, Barcelona 3128760, Spain

Status

Address

Hospital Clinic de Barcelona

Barcelona 3128760, , 08036

Hospital Universitario de Jaen, Jaén 2516395, Spain

Status

Address

Hospital Universitario de Jaen

Jaén 2516395, , 23007

Hospital Beata Maria Ana, Madrid 3117735, Spain

Status

Address

Hospital Beata Maria Ana

Madrid 3117735, , 28007

Hospital Clinico San Carlos, Madrid 3117735, Spain

Status

Address

Hospital Clinico San Carlos

Madrid 3117735, , 28040

Hospital Universitario 12 de Octubre, Madrid 3117735, Spain

Status

Address

Hospital Universitario 12 de Octubre

Madrid 3117735, , 28041

Hospital Universitario Virgen Macarena, Seville 2510911, Spain

Status

Address

Hospital Universitario Virgen Macarena

Seville 2510911, , 41009

Valencia 2509954, Spain

Status

Address

Fundacion Instituto Valenciano de Oncologia (IVO)

Valencia 2509954, , 46009

Valencia 2509954, Spain

Status

Address

Hospital Clinico Universitario de Valencia

Valencia 2509954, , 46010

The Christie, Manchester 2643123, Lancashire, United Kingdom

Status

Address

The Christie

Manchester 2643123, Lancashire, M20 4BX

Clatterbridge Cancer Centre, Liverpool 2644210, Merseyside, United Kingdom

Status

Address

Clatterbridge Cancer Centre

Liverpool 2644210, Merseyside, L69 3GL

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact